Phathom Pharmaceuticals announces common stock offering, no amount given

Phathom Pharmaceuticals (PHAT) announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, in an underwritten public offering. Phathom intends to use the net proceeds from the proposed offering for general corporate purposes, including for working capital and commercialization and research and development expenses. Guggenheim Securities and Cantor are acting as joint bookrunning managers for the proposed offering.